Tibolone induced Bullous pemphigoid

JK Science

Volumn 10, Issue 1, 2008, Pages 26-27

  Tandon, Vishal R ^a   Mahajan, Annil ^a   Sharma, Sudhaa ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

Bullous Pemphigoid; STEAR; Tibolone

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; FOLIC ACID; METHOTREXATE; TIBOLONE;

ADULT; ARTICLE; BULLOUS PEMPHIGOID; CASE REPORT; CHEEK MUCOSA; CLINICAL FEATURE; DISEASE SEVERITY; DYSPHAGIA; EOSINOPHILIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HALITOSIS; HOARSENESS; HUMAN; HYPOALBUMINEMIA; LABORATORY TEST; LEUKOCYTOSIS; MALAISE; MENOPAUSAL SYNDROME; RASH; TREATMENT DURATION;

EID: 58649118835     PISSN: 09721177     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001; 137: 765.
2. Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a South. Indian hospital-their severity and cost involved. Pharmacoepidemiology and Drug Safety 2003: 12: 687-89.
3. Ruocco V, Sacerdoti G: Pemphigus and bullous pemphigoid due to drugs. Int J Dermatol 1991; 30: 307-12
4. Wojnarowska F, Greaves MW, Peachey RD, Drury PL, Besser GM. Progesterone-induced erythema multiforme. J R Soc Med 1985; 78: 407-08.
5. Stranahan D, Rausch D, Deng A, Gaspari A.The role of intradermal skin testing and patch testing in the diagnosis of autoimmune progesterone dermatitis. Dermatitis 2006; 17: 39-42.
6. Sharma S, Mahajan A, Kumar A, Tandon VR. Tibolone: A Selective Tissue Estrogenic Activity regulator. JK Science 2006; 8: 203-04.
7. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
8. Edward IR, Biriell C. Hcirmonisation in pharmacovigilance. Drug Safety 1994: 10: 93-102.